Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management
- 31 December 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 32, S11-S15
- https://doi.org/10.1016/j.ctrv.2006.04.006
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfaEuropean Journal Of Cancer, 2005
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEuropean Journal Of Cancer, 2004
- Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baselineSupportive Care in Cancer, 2004
- Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised studyEuropean Journal Of Cancer, 2003
- Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled studyBritish Journal of Haematology, 2003
- Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietinExperimental Hematology, 2003
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving ChemotherapyJNCI Journal of the National Cancer Institute, 2002
- Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapyBritish Journal of Cancer, 2002
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Cloning and expression of the human erythropoietin gene.Proceedings of the National Academy of Sciences, 1985